BRIC-Institute of Life Sciences (ILS), Bhubaneswar, an autonomous Institute of the Department of Biotechnology, Ministry of Science & Technology, Government of India, engaged in advanced research, invites applications from Indian nationals
Post Graduate degree in Biological Sciences / Post Graduate Degree in a professional Course from a recognized University or equivalent; and the candidates should have cleared any National Level Eligibility test such as (NET / GATE etc.).
Masters Degree from a recognized University or institute in any of the disciplines specified in Pharma, Life Sciences, Biotechnology. Experience in Research and Development in Industry or Academic Institution or Science and Technology Organization.
55% marks in B.Sc / M.Sc. (Bioscience/ Life Sciences). Experience Preference will be given to candidates possessing knowledge or experience in Microsoft Excel.
PhD in Biotechnology, Microbiology, Nanobiotechnology, Bioengineering, Nanotechnology, any other related interdisciplinary engineering and / or science.
Ability to understand and analyses the complex data and performs the activities including accessing the case in Argus, code and enter data. Be fully competent to perform all steps within the case-handling processing.
Hetero is one of worlds leading producers of key Active Pharmaceutical Ingredients and generic formulations with presence in 140+ countries and backed by 30 years of experience in the pharma sector.
You will be responsible for preparation, review and submission of Dossier in ANZ and Emerging Markets as per the applicable regulatory guidance in Emerging Markets.
To monitor the packing area in daily shifts in producing and delivering the committed daily plan volumes, safely, reliably, and with quality standards.
Postgraduate degree in Science / Pharmacology / Life Sciences / Regulatory Science/ Public Health from a recognised University with atleast 6 years of relevant work experience.
Merck known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. In this study, KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with WELIREG
Global pharmaceutical leader, Lupin Limited (Lupin), commemorated the inauguration of its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater, New Jersey. The new location expands Lupin’s presence in the state, which already includes manufacturing and research facilities in Somerset.
MTech, M.S, MSc Pharmacy / Material Science / Biomedical Egg / Nanotechnology / Biochemistry with first division or equivalent mark from reputed institutes with relevant experience